...on the less bright side, the announcement is sufficiently...

...on the less bright side, the announcement is sufficiently vague again in terms of revenue numbers. I know management does not want to provide detailed future financial projection (for fear of getting flogged if projections are missed) but it makes it very difficult for the market to get excited by these type of generic announcements (even if they turn out to be the start of something really good down the track). Market response remains anaemic to these types of announcements...at some stage the team will have to stick out their necks at least a little to keep investors interested even if it is just some sort of guidance as to what this type of new service can generate per "average clinical trial". Ultimately, it is all about revenue numbers (particularly in view of increasing cost base).